Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 115.24B |
| Revenue (ttm) | 10.63B |
| Net Income (ttm) | -479.80M |
| Shares Out | 257.53M |
| EPS (ttm) | -1.86 |
| PE Ratio | n/a |
| Forward PE | 24.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,737,589 |
| Open | 467.06 |
| Previous Close | 469.24 |
| Day's Range | 445.87 - 470.99 |
| 52-Week Range | 391.01 - 519.88 |
| Beta | 0.37 |
| Analysts | Buy |
| Price Target | 519.88 (+16.17%) |
| Earnings Date | Feb 3, 2025 |
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underl... [Read more]
Financial Performance
In 2023, Vertex Pharmaceuticals's revenue was $9.87 billion, an increase of 10.51% compared to the previous year's $8.93 billion. Earnings were $3.62 billion, an increase of 8.96%.
Financial StatementsAnalyst Forecast
According to 30 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is $519.88, which is an increase of 16.17% from the latest price.
News
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
I'm updating my recent “Buy” thesis on Vertex Pharmaceuticals Incorporated — spoiler alert, I am as bullish, if not more so, than I was back in September, despite a recent sell-off. Vertex's CF franch...
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Jefferies has upgraded Vertex Pharmaceuticals Inc. VRTX, citing the company's robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billion opportuni...
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe s...
Undercovered Dozen: Arqit Quantum, CleanSpark, Sezzle, STAG Industrial +
The 'Undercovered' Dozen highlights 12 lesser-covered stocks, showcasing diverse investment opportunities and sparking community discussion on their potential. Xinyu Ru sees Argan, Inc. as undervalued...
Vertex Pharma: Why I Am Buying This Dip
Vertex Pharmaceuticals reported strong Q3 earnings, yet the stock has pulled back, presenting a buying opportunity. The company's robust pipeline, particularly Suzetrigine for acute pain and CASGEVY g...
Buy Signal Flashing For Struggling Biotech
Biotech Vertex Pharmaceuticals (VRTX) has been struggling on the charts over the past few weeks, putting a dent in its now 10% year-to-date gain. The stock's 5.6% post-earnings pop earlier this month ...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Stifel 2024 Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM ET Company Participants Stuart Arbuckle - EVP, COO Conference Call Participants Paul Matt...
Vertex Pharmaceuticals Incorporated (VRTX) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 9:00 AM ET Company Participants Reshma Kewalramani - President and CEO Confer...
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Vertex reported strong Q3 results driven by the growth of the cystic fibrosis franchise and raised the full-year revenue guidance range by $100 million at the mid-point. Casgevy finally generated comm...
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2024 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Dr. Reshma K...
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments.
Vertex Reports Third Quarter 2024 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year produ...
Vertex to Participate in Upcoming November Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive Offic...
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous neph...
Vertex Pharmaceuticals: A Long-Term Growth Monster
Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown gre...
Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly sele...
Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex treatment pr...
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The comp...
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/t...
Biotech stock plays outside of GLP-1 weight-loss market
BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 weight-loss space. The sky-high demand ...
Vertex Pharmaceuticals Incorporated (VRTX) Management presents at Cantor Global Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Cantor Global Healthcare Conference September 17, 2024 9:10 AM ET Company Participants Susie Lisa - SVP, IR Manisha Pai - Executive Director, IR Conf...
Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Vertex stock is significantly undervalued due to the underestimated potential of its pain treatment drug, VX-548, which could become a blockbuster. VX-548 has shown to be more effective than placebos ...
Vertex Pharmaceuticals, Inc. (VRTX) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) Morgan Stanley Conference Call September 5, 2024 11:30 AM ET Company Participants Reshma Kewalramani - President and CEO Charlie Wagner - CFO Conference Cal...
Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Vertex Pharmaceuticals, a leader in Cystic Fibrosis treatment, reported strong financials in Q2 but faces limited growth in CF due to high market penetration. Despite a GAAP net loss in Q2, Vertex rem...
Jupiter Endovascular Receives FDA Approval for U.S. Pivotal Study of Vertex Pulmonary Embolectomy System Using Endoportal Control
MENLO PARK, Calif.--(BUSINESS WIRE)-- #FDA--FDA approves U.S. pivotal trial of Jupiter Endovascular pulmonary embolism system with Endoportal Control technology.